Alirocumab
Composition
Contains Alirocumab, a monoclonal antibody targeting PCSK9; commonly available in 75 mg/mL or 150 mg/mL prefilled syringes or pens.
Indications
Used to lower LDL cholesterol in patients with hypercholesterolemia, including familial cases, and in those with established cardiovascular disease.
Side effects
Injection site reactions, flu-like symptoms, myalgia, nasopharyngitis.
Precautions
Monitor lipid levels and for signs of hypersensitivity; safety in severe hepatic impairment not established.
Contraindications
Hypersensitivity to Alirocumab or any component of the formulation.
Dosage and administration
Typically 75 mg or 150 mg subcutaneously every 2 weeks, or 300 mg monthly based on LDL response.
Countries
Available Forms
Prefilled syringe and prefilled pen for subcutaneous injection.